MannKind Corp.'s shares slid 20.4% to $2.92 Thursday after the company warned the deadline for the Food and Drug Administration to complete its review of the new drug application for a pulmonary arterial hypertension treatment being developed with United Therapeutics Corp. Harpoon Therapeutics Inc. on Monday said the U.S. Food and Drug Administration granted orphan-drug designation to HPN328 for the treatment of small cell lung cancer, or SCLC. When the transactions were called off in the previous session, Stock hit the highs of $36.99, after setting-off with the price of $36.99. GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell . The stock price of Galera Therapeutics Inc (NASDAQ: GRTX) increased by over 118% pre-market today. Developer of novel peptide drugs intended to facilitate treatments for fibrosis and lung conditions. Our lead indications, advanced non-small cell lung cancer and recurrent metastatic melanoma, were selected for their high mutational burden, high level of T cell infiltration and high unmet medical need. Director of CMC. AnHeart Therapeutics Announces Presentation at the European Lung Cancer Congress (ELCC) 2022. Okyo Pharma also filed IPO paperwork as it looks to advance to the clinic with . AN2 Therapeutics (ANTX) has filed to raise capital via an IPO. efficacy and tolerability of HZN-825 in slowing the decline of lung function due to inflammation and fibrosis caused from IPF. The Lung Cancer Research Foundation (LCRF) and the EGFR Resisters, in their second year of a research award partnership, announce their intent to fund at least two new grants specific to EGFR . Whalewisdom has at least 3 13G filings, and 3 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2019-10-31. When investing geniuses David and Tom Gardner . Qx Therapeutics Inc., founded in 2017, is a Delaware corporation operating in Connecticut, US. SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the company has achieved its enrollment target of 40 patients in the EXP-6 cohort of the phase 1/2 registrational . IND Enabling. Onconova Therapeutics, Inc. Research. Since then, MATN shares have increased by 80.6% and is now trading at $0.2185. In 1994, Rothblatt's young daughter was diagnosed with a fatal orphan disease, pulmonary arterial hypertension (PAH). The stock was up 11.1% as of 11:23 a.m. EDT on Tuesday. Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer . The Genprex stock has had an eventful 2021 thus far. Corporate update from portfolio company Harpoon Therapeutics. . Friday, May 28, 2021. View Nurix Therapeutics, Inc NRIX investment & stock information. Phase 1. It is advancing a pipeline of treatments for NTM lung disease caused by MAC. Here is a full analysis of that pipeline and of the catalysts that make this stock a buy. On average, they anticipate Nurix Therapeutics' stock price to reach $47.50 in the next year. 07, 2022 7:52 AM ET Harpoon Therapeutics, Inc. (HARP) By: Dulan Lokuwithana , SA News Editor Grandbrothers . Each of our programs is based on a scientific rationale to identify and treat patients most likely to respond to Mirati's targeted therapies. Matt Karpen joined Lung Therapeutics in 2018 as Director of CMC. Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary diseases and conditions, today announced the appointment of Cory M. Hogaboam . AN2 Therapeutics Appoints Dr. Mel Spigelman, M.D. SAN DIEGO, March 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42 nd Annual Cowen Healthcare Conference, which will be webcast on March 9 at 10:30 a.m. P.T. 7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines. United Therapeutics UTHR reported earnings of $2.35 per share for fourth-quarter 2021, widely missing the Zacks Consensus Estimate of $3.77 per share. . AN2 Therapeutics Inc. filed plans on Friday to go public in an initial public offering in which it reportedly hopes to raise about $75 million. 211 Quality Circle, Suite 210. David Meek, chief executive officer, will represent the company.. Investors and the general public are invited to . 03:42 PM ET. The Menlo Park-based biotech is developing a therapy . Their forecasts range from $28.00 to $64.00. This suggests a possible upside of 225.8% from the stock's current price. to its Board of Directors. Company profile page for Lung Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Overnight correspondence: Computershare. Lung Therapeutics is developing first-in-class medicines for unmet medical needs in fibrosis and lung disease. ACHILLES PIPELINE. View which stocks have been most impacted by COVID-19. The stock has increased 17.9% in the past year. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option. Our lead product is a personalised tumour-derived T cell therapy targeting clonal cancer neoantigens. AN2 is developing epetraborole, a once-daily oral investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM). NEW YORK, March 21, 2022 -- ( BUSINESS WIRE )--AnHeart Therapeutics ("AnHeart"), a clinical-stage . The company's drugs trigger both survival signals for alveolar epithelial cells and destruction signals for unwanted fibrotic cells, enabling medical practitioners to treat idiopathic pulmonary fibrosis and loculated pleural effusion among . Rothblatt sold her telecom stock and started the PPH Cure Foundation to fund PAH research. Pipeline — Aqualung Therapeutics, Corp. DISEASE. View real-time stock prices and stock quotes for a full financial overview. EVANSTON, Ill., March 8, 2022 /PRNewswire/ -- Angiotensin Therapeutics Inc. ("Angiotensin" or the "Company"), a privately-held biopharmaceutical company focused on developing new therapies for . Aqualung Therapeutics has identified an upstream pathway and target which is a key activator of inflammatory cascades that increase the severity of multiple diseases. LONDON, 14 March 2022: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building . Read more here. Matt Karpen. For the readers interested in the stock health of Turning Point Therapeutics Inc. (TPTX). Company's stock value dipped to $31. Mirati Therapeutics started at buy with $202 stock price target at Stifel Nicolaus MarketWatch. The firm is advancing treatments for chronic non-tuberculous mycobacterial, or NTM, lung disease. Lung Therapeutics is based out of Austin. So what Pliant's developing PLN-74809 for people who experience progressive lung scarring that occurs for reasons medicine can't explain yet. AUSTIN, Texas, July 13, 2021--Sharon Morriss, PhD, joins clinical stage biopharmaceutical company Lung Therapeutics as SVP of Clinical Development to advance clinical programs. Why Mirati Therapeutics Stock Is Plunging Today | The Motley Fool However, when the market saw a downturn at the end of February, the stock pulled back to a low of about $4.32. Mar-12-21 11:54AM. This is why it happened. . of Mirati Therapeutics . Thursday, August 26, 2021. Oncternal Therapeutics, Inc. . advanced non-small cell lung cancer with the KRAS-G12C mutation following . AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet need. 09:53 AM ET. Qx Therapeutics Inc. is a drug research and development company aiming to provide innovative treatment toward unmet medical needs in the acute lung injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) disease area. Mr. Karpen brings approximately 20 years of biopharmaceutical experience to Lung Therapeutics, including various leadership positions in process development, process engineering, process scale-up, and technology transfer, cGMP operations support, and clinical and commercial manufacturing. Box 30170. - LTI-03, a Caveolin-1-related peptide, addresses both inhibition of pro-fibrotic signaling, as well as survival of critical epithelial cells- LTI-03 is formulated as a dry powder for direct-to-lung administrationAUSTIN, Texas--(BUSINESS WIRE)--#biopharma--Lung Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing innovative treatments for the treatment of orphan . Lung Therapeutics closes $1,550,000 of its initial Series A Preferred Stock financing, with additional milestone-driven commitments totaling $2,750,000.. AUSTIN, TX — October 28, 2014 — Lung Therapeutics, Inc., a pharmaceutical company focused on niche, orphan drug indications in lung injury and disease, has closed on $1,550,000 in the initial closing of its Series A Preferred Stock . Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The notice included securities offered of Equity,Option, Warrant or Other Right to Acquire Another Security Get the latest Nurix Therapeutics, Inc NRIX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs. Motley Fool +23.77%. SAN DIEGO, Feb. 15, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation who have received at least one prior systemic . Earnings declined 7.3% year over year. Mirati Therapeutics started at equal weight at Morgan Stanley MarketWatch. College Station, TX 77842-3170. AUSTIN, Texas, March 22, 2022--Lung Therapeutics' pioneering compound for the treatment of idiopathic pulmonary fibrosis (IPF), LTI-03, has completed a Phase 1a clinical trial. The South San Francisco, Calif., clinical-stage immunotherapy company said it is currently conducting a Phase 1/2 study of HPN328 in patients with SCLC, a fast-growing . Spero Therapeutics : Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital Setting - Form 8-K Mirati is developing a pipeline of novel therapeutics that directly target the genetic and immunological drivers of cancer to ultimately help improve the lives of patients with cancer. United Therapeutics was founded in 1996 by Martine Rothblatt, an American lawyer, author, and entrepreneur, who created Sirius XM. / 1:30 p.m. E.T. were $8.6 million with $1.7 million in noncash stock-based compensation expense and were $35.7 million for the full year 2021 with $5.9 million in noncash stock . RESEARCH TRIANGLE PARK, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 10,800 shares of G1's common stock and an aggregate of 8,800 restricted stock units (RSUs) to four hired employees under the G1 Therapeutics, Inc. 2021 Sales Force . Feb-16-21 04:03PM. Mirati KRAS inhibitor goes under FDA review for lung cancer. The stock has increased 17.9% in the . Why Sorrento Therapeutics Stock Surged Today . which has generated promising clinical trial results in lymphoma and non-small cell lung cancer. Acute Respiratory Distress Syndrome (ARDS) and Ventilator Induced Lung Injury (VILI)*. United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. --AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet medical need, today . The Series C funding will finance the company's next stage of growth, including the advancement and completion of . Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer Article Stock Quotes (1) FREE Breaking News Alerts . Shares of oncology-focused biotech Mirati Therapeutics (NASDAQ: MRTX) have stumbled across the past few days, with the stock trading in the red by nearly 11% week to date as of Thursday's close. Aqualung Therapeutics is a biotech company developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious "unchecked inflammation" and improve health. NEW YORK and LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced further development of a program for the inhaled delivery of nomacopan to the lung . MENLO PARK, Calif. , March 16, 2022 /PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Dr. Mel Spigelman . This represents 8.81 percent ownership of the company. The company said it intends to list its . To date, Lung Therapeutics has raised a total of $53 million in outside funding. AN2 Therapeutics is preparing for a pivotal test of its boron-based drug candidate for a rare, chronic lung disease. A longer-than-expected regulatory review for the company's lung cancer drug is weighing on its shares today. 2022-02-14 - Lung Therapeutics, Inc. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,235,000 shares of TFF Pharmaceuticals Inc (US:TFFP). The stock has now fallen 33% so far this year, and more than 50% over . Alkermes' earnings have surpassed estimates in each of the trailing four quarters. The stock price of Galera Therapeutics Inc (NASDAQ: GRTX) - a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy (RT) in cancer - increased . Why Onconova Therapeutics Stock Soared Today. . AN2 Therapeutics has filed proposed terms for a $60 million IPO. The company develops MRTX849, a KRAS G12C inhibitor, which is in . - LTI-03, a Caveolin-1-related peptide, addresses both inhibition of pro-fibrotic signaling, as well as survival of critical epithelial cells- LTI-03 is formulated as a dry powder for direct-to-lung administrationAUSTIN, Texas--(BUSINESS WIRE)--#biopharma--Lung Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing innovative treatments for the treatment of orphan . LUNG | Complete Pulmonx Corp. stock news by MarketWatch. Harpoon Therapeutics wins FDA's Orphan Drug Designation for lung cancer therapy Mar. United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.